CareDx CFO Keith Kennedy sells 61,961 shares

The option terms state that one-quarter vested on September 12, 2025, with 1/48th vesting monthly thereafter through September 30, 2028.

Available on EDGAR 11/09/2026 - 06:26 PM EST Accepted by SEC EDGAR 11/09/2026 - 06:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CareDx, Inc. (CDNA) CFO & COO Keith Kennedy exercised options covering 52,422 common shares on November 5, 2026, at a $29.43 exercise price. He sold 61,961 common shares in eight transactions that day under a Rule 10b5-1 trading plan adopted August 6, 2026. Reported per-share amounts ranged from $76.5485 to $83.6000; prices for seven sale tranches were reported as weighted averages. His reported option position after exercise was 48,229 shares.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 10 txns

Insider Kennedy Keith

Role CFO & COO

Sold 61,961 shs ($4.82M)

Approx. gross sale proceeds $4.82M

Approx. exercise cost $1.54M

Share of Position Sold 23.7%

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) F9	52,422	$0.00	$0.00
Exercise	Common Stock	52,422	$29.43	$1.54M
Sale	Common Stock F1, F2	28,256	$76.5485	$2.16M
Sale	Common Stock F1, F3	12,380	$77.4184	$958K
Sale	Common Stock F1, F4	6,897	$78.5875	$542K
Sale	Common Stock F1, F5	7,415	$79.4853	$589K
Sale	Common Stock F1, F6	3,403	$80.3783	$274K
Sale	Common Stock F1, F7	2,710	$81.4041	$221K
Sale	Common Stock F1, F8	300	$82.0767	$25K
Sale	Common Stock F1	600	$83.60	$50K

Holdings After Transaction: Employee Stock Option (right to buy) — 48,229 options (Direct); Common Stock — 199,147 shares (Direct)

Holdings Before and After: Employee Stock Option (right to buy), 100,651 to 48,229 options (Direct); Common Stock, 208,686 to 199,147 shares (Direct)

Footnotes (9)

1. F1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 6, 2026.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.00 to $77.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.07 to $82.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. F9. 1/4th of the shares subject to this option shall vest on September 12, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter through September 30, 2028.

Key Figures

Shares sold: 61,961 shares Options exercised: 52,422 options covering common shares Exercise price: $29.43 per share +3 more

6 metrics

Shares sold 61,961 shares Eight transactions on November 5, 2026

Options exercised 52,422 options covering common shares November 5, 2026

Exercise price $29.43 per share Options exercised on November 5, 2026

Option shares after exercise 48,229 shares Reported following the November 5, 2026 exercise

Reported sale tranche 28,256 shares at $76.5485 per share Weighted-average price for multiple sales on November 5, 2026

Reported sale 600 shares at $83.6000 per share November 5, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, vest

3 terms

Rule 10b5-1 trading plan financial

"the November 5, 2026 sales under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"the reported price for the 28,256-share sale tranche"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vest financial

"the option shares vest monthly through September 30, 2028"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CDNA shares did Keith Kennedy sell?

Keith Kennedy, CareDx, Inc.'s CFO & COO, sold 61,961 shares on November 5, 2026, in eight transactions. Reported per-share amounts ranged from $76.5485 to $83.6000. The sales were under a Rule 10b5-1 plan adopted August 6, 2026.

How many options did CareDx CFO Keith Kennedy exercise?

He exercised options covering 52,422 common shares at a $29.43 exercise price on November 5, 2026. His reported option position after the exercise was 48,229 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennedy Keith

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		M		52,422	A	$29.43	261,108	D
Common Stock	11/05/2026		S(1)		28,256	D	$76.5485(2)	232,852	D
Common Stock	11/05/2026		S(1)		12,380	D	$77.4184(3)	220,472	D
Common Stock	11/05/2026		S(1)		6,897	D	$78.5875(4)	213,575	D
Common Stock	11/05/2026		S(1)		7,415	D	$79.4853(5)	206,160	D
Common Stock	11/05/2026		S(1)		3,403	D	$80.3783(6)	202,757	D
Common Stock	11/05/2026		S(1)		2,710	D	$81.4041(7)	200,047	D
Common Stock	11/05/2026		S(1)		300	D	$82.0767(8)	199,747	D
Common Stock	11/05/2026		S(1)		600	D	$83.6	199,147	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$29.43	11/05/2026		M			52,422	(9)	09/12/2034	Common Stock	52,422	$0	48,229	D

Explanation of Responses:

1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 6, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.00 to $77.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.07 to $82.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. 1/4th of the shares subject to this option shall vest on September 12, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter through September 30, 2028.

	/s/ Jeffrey Adam Novack, Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)